These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 7071809)

  • 21. Biological action and clinical significance of antithrombin III.
    Abildgaard U
    Haematologia (Budap); 1984; 17(1):77-9. PubMed ID: 6724354
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
    Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I
    Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin.
    Marciniak E
    Br J Haematol; 1981 Jun; 48(2):325-36. PubMed ID: 7236529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of inhibitors and the mechanisms of action of antithrombin III.
    Rosenberg RD; Oosta GM
    Prog Clin Biol Res; 1981; 72():179-203. PubMed ID: 7335648
    [No Abstract]   [Full Text] [Related]  

  • 26. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis.
    Tripodi A; Primignani M; Chantarangkul V; Dell'Era A; Clerici M; de Franchis R; Colombo M; Mannucci PM
    Gastroenterology; 2009 Dec; 137(6):2105-11. PubMed ID: 19706293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-thrombin III activity in cerebrovascular accidents.
    Verma SL; Gupta V; Singh JP; Arya R
    J Assoc Physicians India; 1985 May; 33(5):358-9. PubMed ID: 4044503
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor-mediated endocytosis of thrombin-antithrombin III complex by the human monocytoid cell line U937.
    Takeya H; Hamada T; Kume M; Suzuki K
    Biochem Biophys Res Commun; 1994 May; 200(3):1334-40. PubMed ID: 8185584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invalidation of concerns with long-term use of heparin: thrombin/antithrombin III interactions.
    Goosen MF; Sefton MV
    Trans Am Soc Artif Intern Organs; 1982; 28():451-5. PubMed ID: 7164279
    [No Abstract]   [Full Text] [Related]  

  • 31. [Efficacy of antithrombin-III in a case of portal thrombus].
    Goto M; Komatsu M; Yagisawa H; Ohyama Y; Masamune O
    Nihon Shokakibyo Gakkai Zasshi; 1989 Nov; 86(11):2602-5. PubMed ID: 2601124
    [No Abstract]   [Full Text] [Related]  

  • 32. Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis.
    Ota S; Wada H; Abe Y; Yamada E; Sakaguchi A; Nishioka J; Hatada T; Ishikura K; Yamada N; Sudo A; Uchida A; Nobori T
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):279-85. PubMed ID: 18160575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombin and anti-Xa agents in the control of thrombogenesis.
    Fareed J; Shaikh T; Hoppensteadt DA
    Pharmazie; 2001 Oct; 56 Suppl 1():S12-21. PubMed ID: 11686086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of thrombin inactivation by immobilized heparin.
    Byun Y; Jacobs HA; Kim SW
    J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities.
    Vogel GM; van Amsterdam RG; van Dinther TG; Tromp M; Meuleman DG
    Thromb Haemost; 2000 Oct; 84(4):611-20. PubMed ID: 11057859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombin III metabolism in the pulmonary vessel endothelium.
    Proietta M; Pulignano I; Del Porto F; Tritapepe L; Di Giovanni C; Caronti B; Guglielmi R; Aliberti G
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):237-40. PubMed ID: 17413759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired thrombin inhibitor in a patient with liver cirrhosis.
    Barthels M; Heimburger N
    Haemostasis; 1985; 15(6):395-401. PubMed ID: 4076847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of antithrombin III in cirrhosis of the liver.
    Monreal M
    Arch Intern Med; 1987 Apr; 147(4):794, 797. PubMed ID: 3827471
    [No Abstract]   [Full Text] [Related]  

  • 39. The antithrombin titer in pancreatic disease.
    TRACHTMAN B; MATZNER MJ
    Am J Gastroenterol; 1960 Sep; 34():248-51. PubMed ID: 13839129
    [No Abstract]   [Full Text] [Related]  

  • 40. Antithrombin V: Critical evaluation of its assessment and properties.
    VERMYLEN C; VERSTRAETE M
    Thromb Diath Haemorrh; 1960 Dec; 5():267-84. PubMed ID: 13780943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.